スピロノラクトン使用量増加するも、高カリウム血症入院・外来高カリウム血症頻度増加せず

心不全の有無にかかわらずスピロノラクトン使用が増えても、高カリウム血症入院は増加せず、外来高カリウム血症は実際には減少。注意深い観察にて、高カリウム血症増加せずと考えられる。

Randomised Aldactone Evaluation Study (RALES：1999 (from 2847, 5345, and 5246 in the first half of 1999 to 6582, 10 753, and 10 534 by the second half of 2001, and to 8619, 17 844, and 17 649 by 2007)のデータ使用

Spironolactone use and renal toxicity: population based longitudinal analysis
Li Wei, Allan D Struthers, Tom Fahey, Alexander D Watson, Thomas M MacDonald
BMJ 2010;340:c1768 (Published )

Spironolactone prescriptions (top) and prescribing rates (bottom) for different indications in Tayside population between 1994 and 2007. HF=heart failure; LC=liver cirrhosis

Rates of spironolactone prescriptions and hyperkalaemia among patients recently admitted to hospital for heart failure who were receiving angiotensin converting enzyme inhibitors, and rates of aspirin and statins prescribing